Latest Information Update: 20 Oct 2008
At a glance
- Originator AstraZeneca
- Developer Nonindustrial source
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pulmonary hypertension
Most Recent Events
- 09 Jun 2000 New profile
- 09 Jun 2000 Preclinical development for Pulmonary hypertension in Canada (PO)